BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 16, 2025
See today's BioWorld
Home
» China's new STAR board a boon for companies, but caution is required
To read the full story,
subscribe
or
sign in
.
China's new STAR board a boon for companies, but caution is required
Aug. 5, 2019
By
Alex Ho
No Comments
HONG KONG – The new Shanghai Stock Exchange's Science and Technology Innovation board, officially launched in late July, marks China's boldest move yet to attract biopharma and technology companies to its often-turbulent financial markets.
BioWorld